Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iptacopan in aHUS Patients Switching From Anti-C5 Antibody
NCT05935215Phase 3Recruiting
- Sponsor
- Novartis
- Start
- Feb 2024
- Primary completion
- Jul 2028
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 3, open-label, single-arm trial of Iptacopan in atypical hemolytic uremic syndrome (aHUS), sponsored by Novartis. Primary endpoint: Percentage of participants free of TMA manifestation at 12 months. Started Feb 2024; status: recruiting.
02
Drugs
Iptacopan
03
Conditions
atypical hemolytic uremic syndrome (aHUS)
Beyond the preview
Go deeper on NCT05935215.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05935215.